![beem stock price target beem stock price target](https://img.etimg.com/thumb/msid-92243257,width-1070,height-580,imgsize-33044,overlay-etmarkets/photo.jpg)
BEEM has a higher average analyst price target than 312.23 of stocks in the small market cap category.
BEEM STOCK PRICE TARGET HOW TO
Statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat,Ĭlick here for more on how to use these ratings. BEEM has a higher number of analysts covering the stock than 78.4 of Technology stocks. Companies with ratings are not formally covered by a Morningstar analyst, but are Peer companies that do receive analyst-driven ratings.
![beem stock price target beem stock price target](https://s3.tradingview.com/h/Hw0Th5q8_mid.png)
Morningstar Quantitative ratings for equities (denoted on this page by ) are generated using an algorithm that compares companies that are not under analyst coverage to Estimates (2) Low: Projected EPS: High-0.72-0.
BEEM STOCK PRICE TARGET CODE
Davidson is guided by Morningstar, Inc.'s Code of EthicsĪnd Personal Securities Trading Policy in carrying out his responsibilities. BEEM - USA Stock : USD 13.16 1.13 7.91 : Beam Global stock price prediction is an act of determining the future value of Beam Global shares using few different conventional methods such as EPS estimation. That average ranking earns Beam Global an Analyst Rating of 21, which is better than 21 of stocks based on data compiled by. The average price target is 23.333, which means analysts expect the stock to add by 31.31 over the next twelve months. On average, analysts give Beam Global a Buy rating. Is responsible for overseeing the methodology that supports the quantitative fair value. Wall Street is positive on Beam Global ( BEEM ). Lee Davidson, Head of Quantitative Research for Morningstar, Inc., The average twelve-month price prediction for Beam Therapeutics is 122.50 with a high price target of 152.00 and a low price target of 62.00. The average price target is 31.67 with a high forecast of. Past performance is a poor indicator of future performance.There is no one analyst in which a Quantitative Star Rating and Fair Value Estimate isĪttributed to however, Mr. According to the issued ratings of 6 analysts in the last year, the consensus rating for Beam Therapeutics stock is Buy based on the current 1 hold rating and 5 buy ratings for BEAM. Based on 5 Wall Street analysts offering 12 month price targets for Beam Global in the last 3 months.
![beem stock price target beem stock price target](https://media.ycharts.com/charts/e50bc4ca6cd67c3c4d98572843cdbbdd.png)
In no event shall Alpha Spread Limited be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on or relating to the use of, or inability to use, or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. On average, analysts rate Beam Global stock as a buy. The lowest target is 20.2 and the highest is 52.5. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. According to 12 stock analysts, the average 12-month stock price forecast for Beam Global stock is 34.94, which predicts an increase of 136.56. BEEM is currently trading in the 50-60 percentile range relative to its historical Stock Score levels. The Score for BEEM is 54, which is 8 above its historic median score of 50, and infers lower risk than normal. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute, investment advice or recommendations. The current Beam Global BEEM share price is 16.86. Under no circumstances does any information posted on represent a recommendation to buy or sell a security.
![beem stock price target beem stock price target](https://s3.tradingview.com/x/X8we8PZ6_mid.png)
Is not operated by a broker, a dealer, or a registered investment adviser. This technology enables a new class of genetic medicines that targets a single base in the genome without making a double-stranded break in the DNA.